American Diabetes Association

TABLE 2

Percentages of CD4⁺ cell populations in MLN, spleen, and PLN

Feeding	IP	MLN			Spleen			PLN
Feeding	IP			CD25⁺CD4⁺	LAP⁺CD4⁺	CD25⁺CD4⁺	LAP⁺CD4⁺	CD25⁺CD4⁺	LAP⁺CD4⁺
PBS	STZ	7.9 ± 1.1	2.2 ± 0.7	8.4 ± 0.7	3.0 ± 0.4	13.8 ± 1.9	3.7 ± 0.7
Ctl IgG	STZ	7.4 ± 1.1	2.4 ± 0.7	8.0 ± 0.6	3.2 ± 0.6	12.6 ± 2.3	3.9 ± 0.6
aCD3 Ab	STZ	7.6 ± 1.4	2.5 ± 0.6	8.5 ± 0.9	4.3 ± 0.5^*	13.3 ± 2.2	4.5 ± 0.7^†

Feeding	IP	MLN			Spleen			PLN
Feeding	IP			CD25⁺CD4⁺	LAP⁺CD4⁺	CD25⁺CD4⁺	LAP⁺CD4⁺	CD25⁺CD4⁺	LAP⁺CD4⁺
PBS	STZ	7.9 ± 1.1	2.2 ± 0.7	8.4 ± 0.7	3.0 ± 0.4	13.8 ± 1.9	3.7 ± 0.7
Ctl IgG	STZ	7.4 ± 1.1	2.4 ± 0.7	8.0 ± 0.6	3.2 ± 0.6	12.6 ± 2.3	3.9 ± 0.6
aCD3 Ab	STZ	7.6 ± 1.4	2.5 ± 0.6	8.5 ± 0.9	4.3 ± 0.5^*	13.3 ± 2.2	4.5 ± 0.7^†

Data are means ± SD from three experiments (n = 10–14).

P < 0.01;

†

P < 0.05, compared with either the PBS group or the control (Ctl) IgG group. IP, intraperitoneal injection.